1. Parkin, D. M., Bray, F., Ferlay, J. & Pisani, P. Global cancer statistics, 2002. CA Cancer J. Clin. 55, 74–108 (2005).
2. Johnston, J. B. et al. Targeting the EGFR Pathway for Cancer Therapy. Curr. Medicinal Chem. 13, 3483–3492 (2006).
3. Jin, Q. & Esteva, F. J. Cross-talk between the ErbB/HER Family and the type I Insulin- like growth factor receptor signaling pathway in breast cancer. J. Mammary Gland Biol. Neoplasia 13, 485–498 (2008).
4. Gomez, H. L. et al. Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer. J. Clin. Oncol. 26, 2999–3005 (2008).
5. Cameron, D. et al. A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res. Treat. 10, 1007 (2008).